LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Well-differentiated peritoneal papillary mesothelioma located in the uterus of a menopausal patient.

    Caruso, Andrea / Rodríguez Pérez, Alba / Romero Matas, Marta / Pantoja Garrido, Manuel / Gutiérrez Domingo, Álvaro

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

    2021  Volume 42, Issue 5, Page(s) 1578–1579

    MeSH term(s) Female ; Humans ; Menopause ; Mesothelioma/surgery ; Pelvis ; Peritoneum ; Uterus
    Language English
    Publishing date 2021-12-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 604639-3
    ISSN 1364-6893 ; 0144-3615
    ISSN (online) 1364-6893
    ISSN 0144-3615
    DOI 10.1080/01443615.2021.1981269
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2461: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

    Font, Albert / Domenech, Montserrat / Buisan, Oscar / Lopez, Hector / González, Andrea / Etxaniz, Olatz / Matas, Marta / Elias, Xavier / Gomez, Maica / Figols, Mariona / Horneros, Judith / Pardo, Juan Carlos / Notario, Lucia / Ruiz de Porras, Vicenç / Perez, Ignacio / Areal, Joan / Esteve, Anna

    World journal of urology

    2022  Volume 40, Issue 11, Page(s) 2627–2634

    Abstract: Purpose: To develop a risk score based on a prognostic model and a nomogram integrating baseline clinicopathological variables to predict bladder cancer-specific survival (BCSS) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) ... ...

    Abstract Purpose: To develop a risk score based on a prognostic model and a nomogram integrating baseline clinicopathological variables to predict bladder cancer-specific survival (BCSS) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) patients.
    Methods: We retrospectively identified a consecutive sample of 247 MIBC patients treated with cisplatin-based NAC-plus-cystectomy in two Spanish hospitals between 2000 and 2019. Age at MIBC diagnosis, sex, histology, lymphovascular invasion, previous non-MIBC, hydronephrosis, and clinical TNM were included in the initial Cox regression model. A risk score was computed based on the final prognostic model and a nomogram was used to estimate BCSS at 2 and 5 years.
    Results: Median age was 66 years; 89% were males; 83% had pure urothelial carcinoma; 16.2% had previous non-MIBC. Clinical stage was T2N0, T3-4aN0, and Tx-4N + in 24%, 57%, and 19% of patients, respectively. Complete pathological response was seen in 29.4% and downstaging to non-MIBC (ypT1, ypTa, ypTis) in 12.5% of patients. Overall 5-year BCSS was 59%. Four prognostic factors were identified: variant histology, previous non-MIBC, female sex and hydronephrosis. By adding the points attributed to each of these factors, we categorized patients in three groups: low-risk (0 points); intermediate-risk (1-9 points); high-risk (≥ 10 points). Five-year BCSS was 72%, 53%, and 15%, respectively (p < 0.0001).
    Conclusion: We developed a nomogram and risk score based on four baseline clinicopathological characteristics to predict BCSS to NAC-plus-cystectomy in MIBC patients. If validated in prospective studies, this nomogram can be useful for selecting patients likely to benefit from NAC.
    MeSH term(s) Male ; Humans ; Female ; Aged ; Urinary Bladder Neoplasms/pathology ; Neoadjuvant Therapy ; Carcinoma, Transitional Cell/pathology ; Nomograms ; Prospective Studies ; Retrospective Studies ; Neoplasm Invasiveness ; Cystectomy ; Muscles ; Hydronephrosis
    Language English
    Publishing date 2022-09-15
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 380333-8
    ISSN 1433-8726 ; 0724-4983
    ISSN (online) 1433-8726
    ISSN 0724-4983
    DOI 10.1007/s00345-022-04147-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1832: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.

    Tagliamento, Marco / Gennari, Alessandra / Lambertini, Matteo / Salazar, Ramon / Harbeck, Nadia / Del Mastro, Lucia / Aguilar-Company, Juan / Bower, Mark / Sharkey, Rachel / Dalla Pria, Alessia / Plaja, Andrea / Jackson, Amanda / Handford, Jasmine / Sita-Lumsden, Ailsa / Martinez-Vila, Clara / Matas, Marta / Miguel Rodriguez, Ana / Vincenzi, Bruno / Tonini, Giuseppe /
    Bertuzzi, Alexia / Brunet, Joan / Pedrazzoli, Paolo / D'Avanzo, Francesca / Biello, Federica / Sinclair, Alasdair / Lee, Alvin J X / Rossi, Sabrina / Rizzo, Gianpiero / Mirallas, Oriol / Pimentel, Isabel / Iglesias, Maria / Sanchez de Torre, Ana / Guida, Annalisa / Berardi, Rossana / Zambelli, Alberto / Tondini, Carlo / Filetti, Marco / Mazzoni, Francesca / Mukherjee, Uma / Diamantis, Nikolaos / Parisi, Alessandro / Aujayeb, Avinash / Prat, Aleix / Libertini, Michela / Grisanti, Salvatore / Rossi, Maura / Zoratto, Federica / Generali, Daniele / Saura, Cristina / Lyman, Gary H / Kuderer, Nicole M / Pinato, David J / Cortellini, Alessio

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 15, Page(s) 2800–2814

    Abstract: Purpose: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in ... ...

    Abstract Purpose: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice.
    Methods: We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974). Twenty-eight-day case fatality rate (CFR
    Results: By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor-positive, 25.2% (n = 131) human epidermal growth factor receptor 2-positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR
    Conclusion: Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19.
    MeSH term(s) Humans ; Middle Aged ; Female ; SARS-CoV-2 ; COVID-19/epidemiology ; COVID-19/prevention & control ; Breast Neoplasms/epidemiology ; Breast Neoplasms/therapy ; COVID-19 Testing ; Pandemics ; Vaccines
    Chemical Substances Vaccines
    Language English
    Publishing date 2023-01-31
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.01667
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.

    Garrigós, Laia / Saura, Cristina / Martinez-Vila, Clara / Zambelli, Alberto / Bower, Mark / Pistilli, Barbara / Lambertini, Matteo / Ottaviani, Diego / Diamantis, Nikolaos / Lumsden, Ailsa / Pernas, Sonia / Generali, Daniele / Seguí, Elia / Viñas, Gemma / Felip, Eudald / Sanchez, Ana / Rizzo, Gianpiero / Santoro, Armando / Cortellini, Alessio /
    Perone, Ylenia / Chester, John / Iglesias, Maria / Betti, Marta / Vincenzi, Bruno / Libertini, Michela / Mazzoni, Francesca / Zoratto, Federica / Berardi, Rossana / Guida, Annalisa / Wuerstlein, Rachel / Loizidou, Angela / Sharkey, Rachel / Aguilar Company, Juan / Matas, Marta / Saggia, Chiara / Chiudinelli, Lorenzo / Colomba-Blameble, Emeline / Galazi, Myria / Mukherjee, Uma / Van Hemelrijck, Mieke / Marin, Mar / Strina, Carla / Prat, Aleix / Pla, Helena / Ciruelos, Eva Maria / Bertuzzi, Alexia / Del Mastro, Lucia / Porzio, Giampiero / Newsom-Davis, Thomas / Ruiz, Isabel / Delany, Maria Belen / Krengli, Marco / Fotia, Vittoria / Viansone, Alessandro / Chopra, Neha / Romeo, Margarita / Salazar, Ramon / Perez, Ignacio / d'Avanzo, Francesca / Franchi, Michela / Milani, Manuela / Pommeret, Fanny / Tucci, Marco / Pedrazzoli, Paolo / Harbeck, Nadia / Ferrante, Daniela / Pinato, David J / Gennari, Alessandra

    Therapeutic advances in medical oncology

    2021  Volume 13, Page(s) 17588359211053416

    Abstract: Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.: Methods: We report a ...

    Abstract Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.
    Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population.
    Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (
    Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.
    Language English
    Publishing date 2021-11-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359211053416
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top